Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Wave Life Sciences Ltd. (WVE) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/29/2021 GN Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials
03/19/2021 GN Wave Life Sciences to Present at the Third Annual Stifel CNS Day
03/04/2021 GN Wave Life Sciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
02/23/2021 GN Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
02/16/2021 GN Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference  
11/09/2020 GN Wave Life Sciences Reports Third Quarter 2020 Financial Results and Provides Business Update
10/26/2020 GN Wave Life Sciences to Webcast Conference Call of Third Quarter 2020 Financial Results on November 9, 2020
09/28/2020 GN Wave Life Sciences to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
09/23/2020 GN Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
09/22/2020 GN Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares
09/15/2020 GN Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings
09/10/2020 GN Wave Life Sciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
08/10/2020 GN Wave Life Sciences Reports Second Quarter 2020 Financial Results and Provides Business Update
07/27/2020 GN Wave Life Sciences to Webcast Conference Call of Second Quarter 2020 Financial Results on August 10, 2020
05/26/2020 GN Wave Life Sciences to Present at the Jefferies 2020 Virtual Healthcare Conference
05/18/2020 GN Wave Life Sciences Appoints Dr. Ken Rhodes as Senior Vice President, Therapeutics Discovery
05/11/2020 GN Wave Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
02/19/2020 GN Wave Life Sciences to Present at the Cowen and Company 40th Annual Healthcare Conference
12/30/2019 GN Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington's Disease
12/16/2019 GN Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy
09/16/2019 GN Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen
09/06/2019 GN Wave Life Sciences to Host Analyst and Investor Research Day on October 7, 2019
09/05/2019 GN Wave Life Sciences Expands Board of Directors with Three New Appointments
08/26/2019 GN Wave Life Sciences to Present at the Morgan Stanley Global Healthcare Conference
06/27/2019 GN Wave Life Sciences annonce le début de DYSTANCE 51, un essai clinique de phase 2/3 sur le Suvodirsen
06/27/2019 GN Wave Life Sciences gibt den Start von DYSTANCE 51 bekannt, einer klinischen Studie der Phase 2/3 mit Suvodirsen
06/27/2019 GN Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
05/10/2019 GN Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
04/16/2019 GN Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design
04/12/2019 GN Wave Life Sciences to Host Investor Conference Call to Discuss Suvodirsen DMD Clinical Data Being Presented at MDA Clinical and Scientific Conference
04/10/2019 GN Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs
01/24/2019 GN Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares
01/23/2019 GN Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares
01/03/2019 GN Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy